

Paper # 20

Patent Docket P1726R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Leonard Presta Serial No.: 09/483,588 Filed: January 14, 2000 For: POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION	Group Art Unit: 1644 Examiner: D. Saunders <div style="text-align: center;">Certificate of Hand Delivery I hereby certify that this correspondence is being hand delivered to the US Patent and Trademark Office on 3/31, 2003 Reggie Mitchell</div>
--	--

RECEIVED
MAR 16 2003
PM 12:11SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☒ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

The English language translation of WO98/52975, which is marked with an asterisk (*) in the attached PTO-1449 form, is not supplied herewith as it was given to the Examiner by the undersigned on 2/25/03.

A concise explanation of relevance of the items listed on PTO-1449 is:

Serial No.: 09/483,588
Filed: January 14, 2000

Page 2

- ☐ not given
- ☐ given for each listed item
- ☒ given for the listed item(s):
An English language translation of previously cited WO 98/52975.

As to Kabat et al. (1991), the Examiner indicated in the interview of 2/25/03 that a copy of this entire document is available to the PTO Examining Corps. Given the volume of this lengthy document, to avoid excess copying, Applicants are providing herewith a copy of the table of contents, introduction, as well as those pages with constant region sequences, but will be happy to provide copies of other pages of the document (or the entire document) upon request.

- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: February 27, 2003

By: WML

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE